Skip to search formSkip to main contentSkip to account menu

alectinib

Known as: 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile 
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

AF802Alecensaalectinib hydrochloride

Broader (1)

CH5424802
Kinase Inhibitors [MoA]NCIt Antineoplastic Agent TerminologyRO5424802Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
The current study was carried out to compare the effectiveness and safety of different ALK inhibitors in treating ALK+ NSCLC. 
2018
2018
Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.
Review
2017
Review
2017
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
LBA9008Background: Alectinib, a TKI targeting ALK, has shown robust efficacy in crizotinib-naive/resistant ALK+ NSCLC. J-ALEX… 
2017
2017
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
Review
2017
Review
2017
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
A subset of non-small cell lung cancer (NSCLC) tumors (5%) harbors an anaplastic lymphoma kinase (ALK) translocation that drives… 
2016
2016
Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
A study reported in this issue of The Oncologist examined the utility of next-generation sequencing (NGS) in detecting ALK… 
2016
2016
Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging
In the development of anticancer drugs, drug concentration measurements in the target tissue have been thought to be crucial for… 
2016
2016
Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series
In the present study we assessed the activity of the next-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor… 
2016
2016
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
2015
2015
Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
A 75-year-old woman with anaplastic lymphoma kinase (ALK)-rearranged Stage IV lung adenocarcinoma was administered the selective… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)